Switch theme
Sign up to access all valuation multiples
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.
2003
126
LTM Revenue $21.9M
LTM EBITDA -$31.7M
$181M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Avacta Group has a last 12-month revenue (LTM) of $21.9M and a last 12-month EBITDA of -$31.7M.
In the most recent fiscal year, Avacta Group achieved revenue of $31.2M and an EBITDA of -$12.0M.
Avacta Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Avacta Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $21.9M | XXX | $31.2M | XXX | XXX | XXX |
| Gross Profit | $10.1M | XXX | $15.1M | XXX | XXX | XXX |
| Gross Margin | 46% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | -$31.7M | XXX | -$12.0M | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | -38% | XXX | XXX | XXX |
| EBIT | -$42.7M | XXX | -$35.9M | XXX | XXX | XXX |
| EBIT Margin | -195% | XXX | -115% | XXX | XXX | XXX |
| Net Profit | -$48.4M | XXX | -$33.5M | XXX | XXX | XXX |
| Net Margin | -221% | XXX | -107% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Avacta Group's stock price is GBP 0 (or $1).
Avacta Group has current market cap of GBP 145M (or $195M), and EV of GBP 135M (or $181M).
See Avacta Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $181M | $195M | XXX | XXX | XXX | XXX | $-0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Avacta Group has market cap of $195M and EV of $181M.
Avacta Group's trades at 5.9x EV/Revenue multiple, and -6.1x EV/EBITDA.
Equity research analysts estimate Avacta Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avacta Group has a P/E ratio of -4.0x.
See valuation multiples for Avacta Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $195M | XXX | $195M | XXX | XXX | XXX |
| EV (current) | $181M | XXX | $181M | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | -5.7x | XXX | -6.1x | XXX | XXX | XXX |
| EV/EBIT | -4.2x | XXX | -4.3x | XXX | XXX | XXX |
| EV/Gross Profit | 18.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.0x | XXX | -4.7x | XXX | XXX | XXX |
| EV/FCF | -2.0x | XXX | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAvacta Group's last 12 month revenue growth is -76%
Avacta Group's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Avacta Group's rule of 40 is -449% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Avacta Group's rule of X is -334% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Avacta Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -76% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -145% | XXX | -96% | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -449% | XXX | -172% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -334% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 163% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avacta Group acquired XXX companies to date.
Last acquisition by Avacta Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Avacta Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Avacta Group founded? | Avacta Group was founded in 2003. |
| Where is Avacta Group headquartered? | Avacta Group is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Avacta Group have? | As of today, Avacta Group has 126 employees. |
| Who is the CEO of Avacta Group? | Avacta Group's CEO is Dr. Christina Marie Coughlin. |
| Is Avacta Group publicy listed? | Yes, Avacta Group is a public company listed on LON. |
| What is the stock symbol of Avacta Group? | Avacta Group trades under AVCT ticker. |
| When did Avacta Group go public? | Avacta Group went public in 2003. |
| Who are competitors of Avacta Group? | Similar companies to Avacta Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Avacta Group? | Avacta Group's current market cap is $195M |
| What is the current revenue of Avacta Group? | Avacta Group's last 12 months revenue is $21.9M. |
| What is the current revenue growth of Avacta Group? | Avacta Group revenue growth (NTM/LTM) is -76%. |
| What is the current EV/Revenue multiple of Avacta Group? | Current revenue multiple of Avacta Group is 8.3x. |
| Is Avacta Group profitable? | Yes, Avacta Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Avacta Group? | Avacta Group's last 12 months EBITDA is -$31.7M. |
| What is Avacta Group's EBITDA margin? | Avacta Group's last 12 months EBITDA margin is -145%. |
| What is the current EV/EBITDA multiple of Avacta Group? | Current EBITDA multiple of Avacta Group is -5.7x. |
| What is the current FCF of Avacta Group? | Avacta Group's last 12 months FCF is -$88.7M. |
| What is Avacta Group's FCF margin? | Avacta Group's last 12 months FCF margin is -405%. |
| What is the current EV/FCF multiple of Avacta Group? | Current FCF multiple of Avacta Group is -2.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
